Uncover your cancer’s unique genetic and molecular blueprint—often opening doors to breakthrough therapies and clinical trials.
By seeing and understanding how your cancer actually functions, we can match treatments to the real drivers of your disease—not just its location in the body.
Next-generation tests look past organ of origin to pinpoint specific genetic drivers, no matter if you have colon, lung, or breast cancer.
Don’t wait until you’ve run out of standard treatments. Having comprehensive data early can speed up enrollment in clinical trials or advanced therapies.
DNA, RNA, and protein profiles can highlight which targeted drugs or immunotherapies have the best chance of success—and which likely won’t.
Even rare mutations can be a green light for cutting-edge research or smaller clinical trials—where patients often see better results.
You’d never choose a house without seeing it first. Advanced diagnostics do the same for cancer—helping us see every detail before deciding how to treat.
Cancer used to be classified by organ of origin alone (e.g., lung vs. breast). Today, we can analyze tumors at multiple levels:
Quickly tests hundreds of genes at once, uncovering both common and rare mutations.
Shows which mutated genes are actively producing proteins that drive tumor growth.
Detects overexpressed proteins—critical for selecting targeted drugs like antibody-drug conjugates.
By seeing how your cancer actually functions, we can match treatments to the real drivers of your disease—not just its location in the body.
We see people jump from one chemo to the next—missing the fact that a single genetic clue could lead them to a cutting-edge drug or trial.
— Jason Sager, MD
If you’re dealing with a high-risk cancer, don’t rely on partial testing. A comprehensive series of diagnostic tests can steer you to better options ASAP.
If your current therapy is failing or too toxic, advanced diagnostics may reveal a targeted therapy (or trial) with fewer side effects and greater efficacy.
Tumors can evolve. A repeat biopsy—or liquid biopsy—detects new mutations that open up fresh treatment paths.
Sometimes a single gene alteration or protein expression is the key. By spotting it, we can guide you toward an emerging class of drug or clinical trial that fits your case perfectly.
Whether it’s early diagnosis or recurrence, we use advanced testing to uncover fresh paths—often beyond standard chemo.
We’ve come a long way from just looking at cancer under a microscope. Now we can zoom in at the DNA, RNA, and protein level—finding the real drivers of each patient’s tumor.
A next-gen DNA test might reveal a KRAS, ALK, or HER2 mutation in a cancer type where it’s not typically checked—giving you a ticket to a trial that’s pushing boundaries.
Researchers often need exact tumor profiles (e.g., specific RNA or protein markers) to enroll you in small but promising studies.
Diagnostics like PET-CT or PSMA scans can confirm how well a targeted therapy is working, or even open doors to specialized “theranostic” treatments (e.g., radio-labeled antibodies).
In short, advanced diagnostics can be your passport to breakthrough therapies—often years before they become standard care.
We help you figure out if you need next-gen DNA, RNA, and/or protein-level testing—plus advanced imaging options.
Once your report is back, we clarify what it means, from potential drug matches to relevant clinical trials.
If your local oncologist isn’t set up for these tests—or the innovative treatments they reveal—we connect you to specialists who are.
Contact us if you have questions not covered here.
Ready to take diagnostics a step further? Our service includes detailed record review, research, and 1-hour consultation with Dr. Sager.
Explore the services we provide with each consultation:
Get started today—get professional, expert guidance toward the best available treatment, personalized for you.
